ATE490977T1 - Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs - Google Patents

Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs

Info

Publication number
ATE490977T1
ATE490977T1 AT99927164T AT99927164T ATE490977T1 AT E490977 T1 ATE490977 T1 AT E490977T1 AT 99927164 T AT99927164 T AT 99927164T AT 99927164 T AT99927164 T AT 99927164T AT E490977 T1 ATE490977 T1 AT E490977T1
Authority
AT
Austria
Prior art keywords
prostate
tmprss2
diagnosis
therapy
colon cancer
Prior art date
Application number
AT99927164T
Other languages
English (en)
Inventor
Daniel Afar
Rene Hubert
Kahan Leong
Arthur Raitano
Douglas Saffran
Stephen Chappell Mitchell
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of ATE490977T1 publication Critical patent/ATE490977T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99927164T 1998-06-01 1999-06-01 Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs ATE490977T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8759898P 1998-06-01 1998-06-01
US9147498P 1998-06-29 1998-06-29
US12952199P 1999-04-14 1999-04-14
PCT/US1999/012253 WO1999062942A2 (en) 1998-06-01 1999-06-01 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

Publications (1)

Publication Number Publication Date
ATE490977T1 true ATE490977T1 (de) 2010-12-15

Family

ID=27375711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99927164T ATE490977T1 (de) 1998-06-01 1999-06-01 Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs

Country Status (12)

Country Link
US (1) US20060275304A1 (de)
EP (1) EP1082341B1 (de)
JP (2) JP2002517185A (de)
AT (1) ATE490977T1 (de)
AU (2) AU773187B2 (de)
CA (1) CA2329137C (de)
CY (1) CY1111906T1 (de)
DE (1) DE69943020D1 (de)
DK (1) DK1082341T3 (de)
IL (1) IL139988A0 (de)
PT (1) PT1082341E (de)
WO (1) WO1999062942A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1117794A2 (de) * 1998-10-02 2001-07-25 Urogenesys, Inc. Menschlichen gen welches in prostatkrebs, harnblasenkarzinomen, pankreases und dickdarm-krebs exprimiert wird, 36p1a6
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000065067A2 (en) * 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
JP4373637B2 (ja) 1999-08-12 2009-11-25 アジェンシス，インコーポレイテッド ヒト前立腺癌において発現されるｃ型レクチン膜貫通抗原およびその使用
AU2001269766A1 (en) * 2000-06-09 2001-12-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
AU2001276361A1 (en) 2000-06-13 2001-12-24 Bayer Aktiengesellschaft Regulation of human transmembrane serine protease
AU2002218786A1 (en) * 2000-07-12 2002-01-21 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
US6743592B1 (en) * 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
WO2004097358A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008119767A2 (en) * 2007-03-30 2008-10-09 Oryzon Genomics, S. A. Method of nucleic acid analysis.
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5800817B2 (ja) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
ES2676031T3 (es) * 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Cromatografía de afinidad basada en el receptor Fc
DK3215528T3 (da) 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
JP3149185B2 (ja) * 1993-01-15 2001-03-26 ジェネティックス・インスティテュート・インコーポレイテッド エンテロキナーゼのクローニングおよび使用方法
JP3844366B2 (ja) * 1997-02-25 2006-11-08 コリクサ コーポレイション 前立腺ガンの免疫診断のための化合物およびそれらの使用方法
CA2281952C (en) * 1997-02-25 2011-07-19 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) * 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6043033A (en) * 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US20030103981A1 (en) * 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US20020119531A1 (en) * 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
WO2000000605A1 (en) * 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6331427B1 (en) * 1999-03-26 2001-12-18 Millennium Pharmaceuticals, Inc. Protease homologs
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030065157A1 (en) * 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer

Also Published As

Publication number Publication date
US20060275304A1 (en) 2006-12-07
AU2004202306B2 (en) 2007-05-24
DK1082341T3 (da) 2011-03-28
EP1082341A2 (de) 2001-03-14
AU4413699A (en) 1999-12-20
PT1082341E (pt) 2011-02-15
WO1999062942A2 (en) 1999-12-09
IL139988A0 (en) 2002-02-10
DE69943020D1 (de) 2011-01-20
EP1082341B1 (de) 2010-12-08
AU2004202306C1 (en) 2008-05-01
JP2009148265A (ja) 2009-07-09
CY1111906T1 (el) 2015-11-04
CA2329137A1 (en) 1999-12-09
AU2004202306A1 (en) 2004-06-24
JP2002517185A (ja) 2002-06-18
CA2329137C (en) 2011-09-20
AU773187B2 (en) 2004-05-20
WO1999062942A3 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
CY1111906T1 (el) Αντιγονο ογκων χρησιμο για τη διαγνωση και θεραπεια καρκινου του προστατη και του παχεος εντερου
Krüger et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
AU1726199A (en) Metastatic cancer regulated gene
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
DE69738868D1 (de) Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
ATE11372T1 (de) Von vernetztem fibrin abgeleitete radiomarkierte peptide zur bestimmung von thrombi und die dieselben enthaltenden injektierbaren zusammensetzungen.
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
TR200101482T2 (tr) WT1'e özgü imünoterapi için bileşimler
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
ATE207958T1 (de) Äusserliche domäne von c-erbb-2:gp75
ATE169640T1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
CY1109254T1 (el) Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DK0922223T3 (da) Fremgangsmåde til prognosticering af cancer
Wang et al. Antigen expression associated with lymph node metastasis in gastric adenocarcinomas
EP0566571A4 (de) Diagnose von krebs-metastasen durch das mts-1 gen.
Ferrone et al. A human high molecular weight-melanoma associated antigen (HMW-MAA) defined by monoclonal antibodies: a useful marker to radioimage tumor lesions in patients with melanoma
Barra et al. Primary structure of human copper-zinc superoxide dismutase. Cysteine-and tryptophan—Containing peptides
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
Durliat et al. Plasminogen receptors on rat colon carcinoma cells
DE69332583D1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
ATE213773T1 (de) In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür
ATE321885T1 (de) Modulation der neurokrinen differenzierung durch protein 25.1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082341

Country of ref document: EP